Summit Therapeutics

SMMT · NASDAQ

$16.09+$0.52 (+3.34%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $15.57

Latest news

Press releaseOct 19, 7:00 AM ETBusiness Wire
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
NewsOct 13, 12:59 PM ETPiero Cingari
Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today
NewsOct 12, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
NewsOct 7, 12:53 PM ETPiero Cingari
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
NewsOct 5, 3:01 PM ETSurbhi Jain
Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway
Press releaseOct 5, 7:00 AM ETBusiness Wire
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
NewsOct 2, 9:28 AM ETVandana Singh
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
Press releaseOct 2, 2:30 AM ETBusiness Wire
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Press releaseOct 2, 2:30 AM ETBusiness Wire
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
NewsOct 1, 1:43 PM ETSurbhi Jain
Robinhood Traders Just Went on Their Biggest Buying Binge Ever
NewsSep 30, 12:47 PM ETPiero Cingari
Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today
Press releaseSep 29, 12:12 PM ETGlobe Newswire
High-Stakes October has these Biotechs Entering Crucial Stretch
NewsSep 29, 9:12 AM ETVandana Singh
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
Press releaseSep 28, 5:30 PM ETBusiness Wire
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
NewsSep 22, 1:35 PM ET
3 Health Care Stocks With Whale Alerts In Today’s Session
Press releaseSep 22, 6:00 AM ETBusiness Wire
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
NewsSep 21, 1:51 PM ETPiero Cingari
Nasdaq 100 Rallies, Intel Soars 14%: Stock Market Today
Press releaseSep 15, 6:00 AM ETBusiness Wire
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
NewsSep 14, 12:53 PM ETVandana Singh
Why Is Summit Therapeutics Stock Gaining Monday?
Press releaseSep 13, 7:00 AM ETBusiness Wire
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
NewsSep 3, 1:47 PM ETPiero Cingari
Wall Street Rallies as Fed’s Waller Hints at September Rate Hold: Stock Market Today
NewsSep 3, 10:57 AM ETVandana Singh
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
Press releaseSep 2, 5:41 PM ETBusiness Wire
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
NewsAug 26, 1:46 PM ETVandana Singh
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
NewsAug 26, 12:58 PM ETPiero Cingari
Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
NewsAug 26, 10:16 AM ETAvi Kapoor
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
Press releaseAug 25, 6:00 PM ETBusiness Wire
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
NewsAug 25, 12:33 PM ETVandana Singh
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients
Press releaseAug 25, 7:00 AM ETBusiness Wire
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Press releaseAug 12, 9:22 AM ETBusiness Wire
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Press releaseAug 5, 7:00 AM ETBusiness Wire
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
NewsAug 4, 8:15 AM ETAvi Kapoor
Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
Press releaseJul 27, 8:52 AM ETPRNewswire
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
NewsAug 27, 8:11 AM ETAvi Kapoor
JM Smucker, Baidu And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsOct 2, 4:18 PM ETChris Katje
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today

10 Health Care Stocks With Whale Alerts In Today’s Session

Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%

Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Robinhood Traders Just Went on Their Biggest Buying Binge Ever

Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today

High-Stakes October has these Biotechs Entering Crucial Stretch

AstraZeneca Invests in Summit Therapeutics after Year of Speculation

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

3 Health Care Stocks With Whale Alerts In Today’s Session

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

Nasdaq 100 Rallies, Intel Soars 14%: Stock Market Today

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Why Is Summit Therapeutics Stock Gaining Monday?

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Wall Street Rallies as Fed’s Waller Hints at September Rate Hold: Stock Market Today

Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

JM Smucker, Baidu And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?